Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Economics of Health Care Markets and Innovation (EHCI)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Individuals, Markets and Organisations
Panel description: Economics, finance , management
Countries involved: France
Call: ERC ADVANCED GRANTS (ERC-2023-ADG, 2023)
Start date: 2024-09-01
End date: 2029-08-31
Duration (months): 60.0
Total project cost (EUR): 1421250.0
EU funding (EUR): 1421250.0
Participants: 2
Project status: SIGNED

Medical progress over the last century has undoubtedly improved our well-being. However, the equal access to health care and its economic sustainability are challenged by the scientific revolutions of genetics, the nature and extent of new risks and the growing externalities across countries that put at risk the production of health care public goods. The development of new cell and gene technologies holds the potential for creating therapies for conditions like cancers and genetic diseases. However, the associated costs may be prohibitively high. It is crucial to find ways to provide an environment where such innovations are produced in the most efficient and accessible way. Furthermore, the incentives provided by intellectual property protection, which drive innovation, and measures to reduce research and development costs, are vulnerable to international free riding and can be in contradiction with competition policy. The objective of this research program is to conduct policy-relevant analyses that address these challengesand contribute to a better understanding of optimal public policies and regulatory interventions. Several research directions will be pursued focusing on national price regulation. These regulations must consider potential cross-country externalities arising from explicit reference pricing used by regulators, international trade considerations, and the need to collectively finance socially valuable innovations. The exploration of alternative pricing mechanisms, such as indication-based pricing, quantity-based pricing, and exclusivity extension rules, will be undertaken as potential tools to improve efficiency. Moreover, the promotion of pharmaceuticals, both by the private sector and public entities, will be examined. Additionally, the research program will involve the analysis of innovation and competition policies, ranging from drug research and development projects to healthcare markets.

Keywords: empirical industrial organization,regulation,innovation,competition,pharmaceuticals,advertising
In cellulo cryo electron tomography study on the structural regulation of nuclear pore complexes by the Nup210 luminal ring (ProtectNPC)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-11-01
End date: 2027-10-31
Duration (months): 24.0
Total project cost (EUR): 217965.12
EU funding (EUR): 217965.12
Participants: 1
Project status: SIGNED

The nuclear envelope (NE) is a double-membrane structure that encloses and protects the genetic material in eukaryotes. It is intermitted by nuclear pore complexes (NPCs), which form channels across the NE and mediate nucleocytoplasmic exchange. High tension in the NE is known to invoke NPC dilation, involving structural changes of the NPC scaffold. It is unknown to date, which NPC constituents limit maximum dilation to prevent NPC disintegration under high NE tension, and if disintegration of NPCs can result in NE rupture and nucleocytoplasmic mixing. A putative candidate for protecting NPC structure under mechanical strain is the nucleoporin 210 (Nup210). It is upregulated in several cancers, emerging as a biomarker for breast cancer metastasis and important for cellular adhesion and migration. Nup210 mainly resides in the lumen of the NPC-associated NE und forms a luminal ring (LR), which surrounds the entire residual NPC. In the proposed project, I will assess the role of the Nup210 LR in maintaining NPC structure to prevent disintegration and potential NE rupture under mechanical strain. For this, I will apply focused ion beam milling, cryo electron tomography and advanced image processing techniques to control and Nup210 depleted human cells under differing conditions of NE tension. The comparison of NPC structures will reveal how the Nup210 LR contributes to NPC structural integrity on a molecular level. I will further resolve the conformational landscape of the Nup210 LR to determine whether it elastically accommodates NPC dilation and re-constriction. These structural studies will be complemented and functionally validated by analysing nucleocytoplasmic exchange and NE rupture in the presence and absence of Nup210 in cells. The insights into NPC scaffold integrity and the contribution of the Nup210 LR, and the workflows developed in this project will be of great interest to the structural biology, NPC, NE and mechanobiology research communities.

Keywords: nuclear pore complex nup210 fib milling cryoet nucleocytoplasmic transport nuclear envelope rupture mechanobiology
“OUSAR” Omniphonic Underwater Speaker Applications in Relaxation (OUSAR)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 4000000.0
EU funding (EUR): 4000000.0
Participants: 1
Project status: CLOSED

Established in 2020, our Sound Technology Engineering Startup, created a highly performing TRL 7 Underwater Electrodynamic Speaker prototype. With an initial purpose to ward off predatory fish, we discovered they were adapting to frequency modulation. With our patented first version, we launched more applicative R&D and new opportunities emerged for human users. Since 2021 we improved our device producing wide range sound waves of ultimate quality, allowing the body Inner Ear, through Bone Conduction, to recognise signals, music and even human voice. This sound is named “omniphonic” as perceived from “inside” oneself. Truly different from eardrums’ stereophony. Tested in over 20 large swimming pools with a range of different adults, we used surveys to define customers’ expectations and identify our target markets. A ten minutes exposure observed on more than 300 persons showed direct impact on well-being, reaching deep relaxation when affected by Stress, Fears, and up to reducing PTSD. Our current aim is to develop and produce three certified products for (i) public swimming pools, (i) individual pools, and (iii) an individual listening miniaturised system for bedridden persons. The fullest customers’ coverage is composed of two groups, first, persons physically able to float individually in a pool with no contraindications, and a second one with disabled patients because of age, wounds, prosthetic devices, traumatic or mental condition. The second goal is to conduct Preclinical and Clinical testing for safety and efficiency. By matching ISO 13485 standards for design and manufacture of medical devices, we will submit a premarket application to the relevant health authorities. In two years time or less we will have off-the-shelf products for professionals and informed users, bringing a new and efficient solution to control and reduce anxiety for a better public health of the youngs, adults, elders and people in need of help.

Keywords: underwater,electrodynamic,speaker,bone conduction,well being,deep relaxation,ptsd reduction,medical support
PAN EUROPEAN ASSESSMENT, MONITORING, AND MITIGATION OF CHEMICAL STRESSORS ON THE HEALTH OF WILD POLLINATORS (WILDPOSH)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Biodiversity and Ecosystem Services
Action type: Research and Innovation actions
Countries involved: Belgium,Poland,Serbia,Germany,Italy,France,United Kingdom,Spain,Bulgaria,Estonia,Sweden
Call: Better understanding of routes of exposure and toxicological and ecological impacts of chemical pollution on terrestrial biodiversity (HORIZON-CL6-2023-BIODIV-01, 2023)
Start date: 2024-01-01
End date: 2027-12-31
Duration (months): 48.0
Total project cost (EUR): 4893596.25
EU funding (EUR): 4893596.25
Participants: 19
Project status: SIGNED

Wild fauna and flora are facing variable and challenging environmental disturbances. One of the animal groups that is most impacted by this, concerns pollinators. Pollinators face multiple threats, but the spread of anthropogenic chemicals (i.e. pesticides) form a major potential driver of these threats. WildPosh is a multi-actor, transdisciplinary project whose overarching mission and ambition are to significantly improve the evaluation of risk to pesticide exposure of wild pollinators, and enhance the sustainable health of pollinators and pollination services in Europe. As chemical exposure varies geographically, across cropping systems, inside the crop system and among pollinators, we will characterise exposure by doing fieldwork in 4 countries representing the four main climatic European regions, Mediterranean, Atlantic, Continental and Boreal climate in Germany, England, Estonia and Spain. We will also develop experiments in controlled conditions on different species of bees, syrphid flies, moths and butterflies, and collect in silico data on their traits and on toxicity of pesticides. With WildPosh, we aim to achieve the following objectives: 1. Determining the real-world agrochemical exposure profile of wild pollinators at landscape level, within and among sites; 2. Using integrated and controlled laboratory and semi-field experiments to characterise causal relationships between pesticides and pollinator health; 3. Building an open database on pollinator traits/distribution and chemicals to define exposure and toxicity scenarios by developing databases on ecological traits and the spatial distribution of pollinators in relation to their potential exposure to pesticide; 4. Proposing integrated systems-based risk assessment tools for risk assessment for wild pollinators; and 5. Driving policy and practice through interactive innovation, meeting the need for monitoring tools, novel and innovative screening protocols for practice and policymaker use.

Keywords: toxicology,pollution and climate,bees,syrphid flies,moths and butterflies
Planning for Sustainable Ocean Use in Antarctica Under Global Environmental Change (PLAnT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Human Mobility, Environment, and Space
Panel description: Human geography, demography, health, susta inability science, territorial planning, spatial analysis
Countries involved: Portugal
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-03-01
End date: 2029-02-28
Duration (months): 60.0
Total project cost (EUR): 1499819.0
EU funding (EUR): 1499819.0
Participants: 2
Project status: SIGNED

Planning of marine areas is being developed worldwide to support ocean sustainability. However, few existing marine spatial planning (MSP) initiatives consider climate change explicitly. This is a critical oversight in a rapidly changing world. At the same time, no formal MSP initiatives are envisioned for Antarctica; it is the only ocean basin globally without MSP under development. Antarctica is changing rapidly with potential repercussions around the planet, particularly for sea-level rise, climate regulation, and marine ecosystems functioning. Developing integrated, sustainable MSP for Antarctica is now more fundamental than ever. Excluding climate effects from MSP will lead to plans that are maladaptive and inefficient in sustaining marine ecosystems and their use under change. By contrast, if designed with climate objectives, MSP can provide substantial benefits while requiring few trade-offs. Efforts must be thus put together to effectively move towards climate-smart MSP in Antarctica and globally. Yet, contextual idiosyncrasies (political, social, economic) limit the effectiveness of such efforts. Understanding what challenges hinder the development of climate-smart MSP, in Antarctica and globally, and pointing ways to overcome such challenges is key. PLAnT will take up, for the very first time, such critical task. It will assess social-ecological vulnerabilities; build future scenarios; support area-based climate action and dynamic solutions; conduct governance analyses; and foster a paradigm shift on how to plan for sustainability and equity under change. Research on complex social-ecological systems rarely leads to one-size solutions, and there is a risk that solutions identified in PLAnT are context specific. Still, PLAnT will inspire nations worldwide to finding pathways and solutions to support ocean sustainability. At a time when the latter is firmly established in the international agenda, taking a leap forward on this topic is ground-breaking.

Keywords: marine spatial planning climate change antartica southern ocean sustainable ocean use marine conservation ocean policy ocean governance stakeholder perceptions social ecological systems dynamic management
enabling Clinical Research in Emergency and Acute care Medicine through automated data extraction (eCREAM)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
Action type: Research and Innovation actions
Countries involved: Italy,Greece,France,Switzerland,United Kingdom,Slovenia,Slovakia,Poland
Call: Innovative tools for use and re-use of health data (in particular of electronic health records and/or patient registries) (HORIZON-HLTH-2021-TOOL-06, 2021)
Start date: 2022-09-01
End date: 2027-08-31
Duration (months): 60.0
Total project cost (EUR): 7294250.0
EU funding (EUR): 7294249.0
Participants: 11
Project status: SIGNED

To date, the possibility of doing research on quality-of-care assessment in emergency medicine has clashed against sustainability problems. The vast number of patients visiting an ED and the staff shortage that often afflicts these departments make ad hoc data collections unattainable. The only way to fill the gap between the need for clinical research and the availability of robust data is to directly extract such data from the EDs electronic health records (EHRs), avoiding dedicated data collection. Achieving this goal would enable distributed clinical research, which is now too much restricted to academic centres, and allow to leverage of clinical information to address a multitude of research questions. Nonetheless, obtaining consistent data from EHRs is a complex task. While a small part of the data registered in EHRs is structured (such as lab test results and vital parameters), most of the useful information on patients' conditions is variably contained in free text (e.g. presence of signs and symptoms, suspected and confirmed diagnosis, anamnesis, etc.). Moreover, as a proactive follow-up of ED patients is unfeasible, relying on the existing data sources is also necessary to measure the outcome of the patients at the most appropriate time interval for the research question of interest. This proposal has three main aims: 1) to develop new technical solutions to extract reliable clinical information from structured and unstructured data contained in different electronic patient files; 2) to FAIRify (i.e. making data Findable, Accessible, Interoperable, and Re-usable) the established databases for clinicians, researchers, health policymakers and citizens while respecting the European and national legislations; 3) to pilot the exploitation of the established databases in two relevant use cases: i) assessment of ED propensity to hospitalise a patient, and ii) development of a dashboard to be used by citizens and policymakers to improve the quality of care in ED.

Keywords: emergency medicine data sharing electronic health records
Uncovering molecular and cellular mechanisms of immune cell trafficking across the blood-CSF barrier in autoimmunity (CNS Hidden Door)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing , nervous system  function and dysfunction , systems neuroscience  and modelling , biological basis of cognitive processes and of behaviour, neurological and mental disorders – In humans and all other organisms
Countries involved: Israel
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2023-05-01
End date: 2028-04-30
Duration (months): 60.0
Total project cost (EUR): 2412448.0
EU funding (EUR): 2412448.0
Participants: 1
Project status: SIGNED

Immune cells continuously traverse our body, crossing vascular and epithelial barriers; from lymphatic organs into the blood, and from the blood into various tissues for surveillance or to fight infection. However, the brain has long been considered an immune-privileged organ. Barriers protecting the brain against infection or harmful toxic agents were also thought to block entry of immune cells, leaving immune functions to brain-resident microglia cells. This dogma was recently overturned when it became clear that immune cells cross, mainly for surveillance, especially at the Blood-CSF barrier. Furthermore, while harmful immune cell trafficking is a hallmark of brain autoimmunity, e.g. Multiple Sclerosis and Neuro-Lupus, enhanced trafficking might help to fight brain tumours, and even to resolve neurodegenerative conditions, e.g. Alzheimer’s Disease. Yet the study of immune cell trafficking across the Blood-CSF barrier is severely hampered by a shortage of suitable methodologies. We investigated Blood-CSF barrier dysfunction in Lupus and discovered a brain lymphoid structure with enhanced immune cell trafficking. Dominant transepithelial leukocyte migration (through, rather than in between, cells) will enable us to catch the trafficking events ‘red-handed’ and to identify molecular and cellular trafficking mechanisms. Harnessing innovative methodologies involving single-cell RNAseq, Super-Resolution microscopy, Imaging cytometry, and genetic/pharmacological interventions, we aim to decipher the fundamental question of how leukocytes enter the brain. We will classify specialized immune and epithelial barrier cell types, identify trafficking molecular pathways, and develop approaches to regulate the process. We will also assess this barrier involvement in the pathobiology of human Neuro-Lupus disease. Understanding immune trafficking mechanisms may be the key to a specialized brain portal, leading to therapeutics that can modulate brain-immune interactions.

Keywords: blood csf barrier,choroid plexus,transcellular migration,diapedesis,lupus,npsle,terthiery lymphoid structure
Bacterial-Derived Therapeutics based on CircRNAs (BacTheRNA) (BacTheRNA)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Ireland
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-07-16
End date: 2024-05-15
Duration (months): 22.0
Total project cost (EUR): 172750.08
EU funding (EUR): 172750.08
Participants: 2
Project status: TERMINATED

RNA therapeutics are a rapidly growing field of research, thanks to their enormous potential. However, production costs and delivery systems represents the major issues for their widespread use in clinics. BacTheRNA aims at overcoming these issues by developing novel circular RNA (circRNA)-based therapeutics using recombinant food-grade bacteria. CircRNAs are advantageous over their linear counterpart, for their stability due to their intrinsic resistance to nucleases (which cannot cut circular molecules without free ends). Their production costs are thus lower, as they do not need chemical or enzymatic modifications. Moreover, production in bacteria is simpler than chemical synthesis and it is scalable, with further reduced production costs. CircRNAs will be either purified as naked molecules or will be directly secreted by the bacteria in extracellular vesicles (EVs) embedding targeting moieties. Importantly, non-immunogenic circRNAs can be designed. Intriguingly, BacTheRNA will demonstrate that it is possible to include targeting moieties directly through programming of circRNAs natural packaging, i.e. by expressing appropriate surface ligands on recombinant EVs. Finally, the potential to reach increased efficiency thanks to the possibility of amplification through rolling circle mechanisms is yet another innovative aspect of these next-generation RNA therapeutics. As a proof-of-concept, circRNAs produced in BacTheRNA will be applied to Type 2 Diabetes Mellitus (T2DM) as a model target disease. Nevertheless, BacTheRNA will demonstrate a general strategy, which can potentially be exploited in several other pathologies that may benefit of RNA therapeutics approaches.

Keywords: circrna,bacteria,rna therapeutics